AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8346498 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge during prolonged treatment with nicotine
Number of subjects: 20
Study 2940370 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment methods (B regimen)
Number of subjects: 0
Study 2940370 — intervention group
Group type: COMPARATOR
Intervention: Traditional management (A regimen)
Number of subjects: 0
Study 30089655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice (n = 816)
Number of subjects: 1602
Study 30089655 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 786)
Number of subjects: 1602
Study 30089655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice
Number of subjects: 1602
Study 30089655 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1602
Study 26809850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 26809850 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 188
Study 26809850 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 188
Study 25313098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mating motive prime
Number of subjects: 0
Study 25313098 — intervention group
Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 0
Study 23913968 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 48
Study 23913968 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab/low-dose rabbit anti-thymocyte globulin (Bas/rATG)
Number of subjects: 48
Study 21429514 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched diet (1.1 g protein/100 mL of feeding formula)
Number of subjects: 51
Study 21429514 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 51
Study 21429514 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched diet
Number of subjects: 51
Study 18344756 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated kinetic perimetry (SKP)
Number of subjects: 10
Study 18344756 — intervention group
Group type: COMPARATOR
Intervention: Goldmann manual kinetic perimetry (GVF)
Number of subjects: 10
Study 17006921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.075 mg) twice daily for 3 months
Number of subjects: 64
Study 17006921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12687864 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing driven by contractility
Number of subjects: 23
Study 12687864 — intervention group
Group type: COMPARATOR
Intervention: DDI pacing
Number of subjects: 23
Study 11110232 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 141
Study 11110232 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 141
Study 8649238 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (breast-fed)
Number of subjects: 20
Study 8649238 — intervention group
Group type: COMPARATOR
Intervention: Formula without AA and DHA (unsupplemented)
Number of subjects: 20
Study 8649238 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with AA and DHA (supplemented)
Number of subjects: 20
Study 8649238 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with corn oil (for neonates with phenylketonuria)
Number of subjects: 20
Study 1545089 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled gallopamil (20 mg)
Number of subjects: 6
Study 1545089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3944721 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-sitting position with male physician
Number of subjects: 112
Study 3944721 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with female physician
Number of subjects: 112
Study 3944721 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-sitting position with male physician (previous pelvic examination)
Number of subjects: 112
Study 3944721 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-sitting position with female physician (never had pelvic examination)
Number of subjects: 112
Study 29373513 — intervention group
Group type: COMPARATOR
Intervention: 1.5 servings/day of chopped almonds
Number of subjects: 18
Study 29373513 — intervention group
Group type: COMPARATOR
Intervention: 1.5 servings/day of whole almonds
Number of subjects: 18
Study 29373513 — intervention group
Group type: COMPARATOR
Intervention: 1.5 servings/day of almond butter
Number of subjects: 18
Study 26795716 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback group (8 individuals)
Number of subjects: 18
Study 26795716 — intervention group
Group type: COMPARATOR
Intervention: Nonbiofeedback group (10 individuals)
Number of subjects: 18
Study 24342688 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% steam‐flaked brown rice (BR)
Number of subjects: 9
Study 24342688 — intervention group
Group type: COMPARATOR
Intervention: 40% steam‐flaked corn
Number of subjects: 9
Study 21521379 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triiodothyronine ointment applied twice daily for 12 weeks
Number of subjects: 10
Study 21521379 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 12 weeks
Number of subjects: 10
Study 15965585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm BASIS training
Number of subjects: 28
Study 15965585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm BASIS training with APB representation at pre test
Number of subjects: 28
Study 15965585 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (non‐intensified vs. intensified therapy, Bobath approach)
Number of subjects: 28
Study 11809594 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1553
Study 11809594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553
Study 9673554 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 25 to 30 ml/kg body weight at 37 degrees C infused under the right hemidiaphragm (Group C)
Number of subjects: 300
Study 9673554 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline at room temperature infused under the right hemidiaphragm and suctioned after deflation (Group D)
Number of subjects: 300
Study 9673554 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infused and suctioned as in Group D, but with a subhepatic closed drain left for 24 hours (Group E)
Number of subjects: 300
Study 9673554 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal infusion, no subhepatic drain (Group A)
Number of subjects: 300
Study 9673554 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal infusion but a subhepatic closed drain left for 24 hours (Group B)
Number of subjects: 300
Study 8079849 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ml of iohexol 350
Number of subjects: 902
Study 8079849 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of iohexol 300
Number of subjects: 902
Study 8079849 — intervention group
Group type: COMPARATOR
Intervention: 150 ml of diatrizoate meglumine 60%
Number of subjects: 902
Study 8079849 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 240
Number of subjects: 902
Study 2642435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0
Study 2642435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1017281 — intervention group
Group type: EXPERIMENTAL
Intervention: New tar gel
Number of subjects: 0
Study 1017281 — intervention group
Group type: COMPARATOR
Intervention: Crude coal tar
Number of subjects: 0
Study 31390293 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO‐delivered palliative care education program (10 interactive sessions over five months)
Number of subjects: 353
Study 31390293 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO‐delivered palliative care education program
Number of subjects: 353
Study 30075763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge-TFF3 test
Number of subjects: 120
Study 30075763 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26649555 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF
Number of subjects: 66
Study 26649555 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF
Number of subjects: 66
Study 24906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (n = 7)
Number of subjects: 14
Study 24906374 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n = 7)
Number of subjects: 14
Study 22327131 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin 60 μg/kg daily for three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning.
Number of subjects: 155
Study 22327131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 22327131 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 155
Study 20337955 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 20337955 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine combination
Number of subjects: 40
Study 18380946 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 127
Study 16128481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related fitness school-based program and home program with parent involvement
Number of subjects: 238
Study 16128481 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical education and nutrition education program
Number of subjects: 238
Study 11860649 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bupivacaine
Number of subjects: 99
Study 11860649 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked swabs (Control)
Number of subjects: 99
Study 10449850 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with polytetrafluoroethylene (PTFE)
Number of subjects: 35
Study 10449850 — intervention group
Group type: COMPARATOR
Intervention: Repair without polytetrafluoroethylene (PTFE)
Number of subjects: 35
Study 7887701 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-spectrum (nafcillin)
Number of subjects: 78
Study 7887701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midspectrum (cephapirin)
Number of subjects: 78
Study 7887701 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum (ceftriaxone)
Number of subjects: 78
Study 7887701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 78
Study 2297305 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin
Number of subjects: 5
Study 2297305 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 5
Study 358366 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (ES), operated within 7 days after the onset of acute symptoms
Number of subjects: 100
Study 358366 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (DS), operated 2-3 months after the acute episode
Number of subjects: 100
Study 31498447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 30207
Study 31498447 — intervention group
Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 30207
Study 31498447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RA-DNI
Number of subjects: 30207
Study 31498447 — intervention group
Group type: COMPARATOR
Intervention: Patients without RA
Number of subjects: 30207
Study 31256082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic motor dual task training
Number of subjects: 50
Study 31256082 — intervention group
Group type: COMPARATOR
Intervention: Land motor dual task training
Number of subjects: 50
Study 28735851 — intervention group
Group type: COMPARATOR
Intervention: Added fiber (AF)
Number of subjects: 12
Study 28735851 — intervention group
Group type: COMPARATOR
Intervention: No added fiber (NF)
Number of subjects: 12
Study 28735851 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole black beans (BN)
Number of subjects: 12
Study 26039688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0
Study 26039688 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 40 mg/day
Number of subjects: 0
Study 26039688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23564564 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN group (31 patients received Peg‐IFN subcutaneously at a dose of 50 μg per week for 12 months)
Number of subjects: 93
Study 23564564 — intervention group
Group type: COMPARATOR
Intervention: Control group (62 patients followed only, no adjuvant therapies)
Number of subjects: 93
Study 22055259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791
Study 22055259 — intervention group
Group type: COMPARATOR
Intervention: Control (standard glucose control)
Number of subjects: 1791
Study 19393000 — intervention group
Group type: EXPERIMENTAL
Intervention: Xolair (anti-IgE treatment) for 16 weeks in patients with high IgE fraction (>3.8%)
Number of subjects: 38
Study 19393000 — intervention group
Group type: EXPERIMENTAL
Intervention: Xolair (anti-IgE treatment) for 16 weeks in patients with low IgE fraction (<1%)
Number of subjects: 38
Study 19393000 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks in patients with high IgE fraction (>3.8%)
Number of subjects: 38
Study 19393000 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks in patients with low IgE fraction (<1%)
Number of subjects: 38
Study 16393304 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3) administered at a dose of 1.2 x 10(10) CFU, twice daily, for 5 days
Number of subjects: 87
Study 16393304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16393304 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3) in rotavirus infection
Number of subjects: 87
Study 16393304 — intervention group
Group type: COMPARATOR
Intervention: Placebo in rotavirus infection
Number of subjects: 87
Study 16393304 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3)
Number of subjects: 87
Study 15316913 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11357896 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg IV
Number of subjects: 31
Study 11357896 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg orally
Number of subjects: 31
Study 11357896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9393527 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine-enhanced MR imaging
Number of subjects: 28
Study 7949622 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 0.7 IU/kg/week (group B)
Number of subjects: 130
Study 7949622 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 1.4 IU/kg/week (group C)
Number of subjects: 130
Study 7949622 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 130
Study 2897559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily)
Number of subjects: 105
Study 2897559 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus cefuroxime (combination therapy)
Number of subjects: 105
Study 2897559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 105
Study 2897559 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus cefuroxime
Number of subjects: 105
Study 27536927 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 27536927 — intervention group
Group type: EXPERIMENTAL
Intervention: Church leader support and strength of parishioners' connection to the church
Number of subjects: 0
Study 24356320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III Low Motor/Vision accommodated version
Number of subjects: 19
Study 24356320 — intervention group
Group type: COMPARATOR
Intervention: Standard Bayley-III
Number of subjects: 19
Study 23704089 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (L-DNR)
Number of subjects: 521
Study 23704089 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 521
Study 20940718 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (6 cycles: 3 concomitant and 3 post-radiotherapy)
Number of subjects: 97
Study 20940718 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/fluorouracil (4 cycles: 2 concomitant and 2 post-radiotherapy)
Number of subjects: 97
Study 20940718 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 97
Study 20940718 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/fluorouracil
Number of subjects: 97
Study 17940996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity measures in treatment groups
Number of subjects: 0
Study 17940996 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards model for time-to-event outcomes
Number of subjects: 0
Study 17940996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prentice criterion
Number of subjects: 0
Study 16816151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing (Immediate Postconcussion Assessment and Cognitive Testing)
Number of subjects: 0
Study 16816151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Number of subjects: 0
Study 16816151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing and symptom assessment
Number of subjects: 0
Study 16816151 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninjured athletes)
Number of subjects: 0
Study 16816151 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom and neurocognitive test results
Number of subjects: 0
Study 12504932 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 548
Study 12504932 — intervention group
Group type: COMPARATOR
Intervention: Delay until the obstetrician is no longer uncertain
Number of subjects: 548
Study 10378821 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (600 mg/day)
Number of subjects: 43
Study 10378821 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (300 mg/day)
Number of subjects: 43
Study 10378821 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 43
Study 10378821 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 43
Study 8906524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 1632
Study 8906524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1632
Study 1864770 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weeks)
Number of subjects: 27
Study 1864770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 27
Study 6638451 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthetic technique of fentanyl and methohexitone
Number of subjects: 0
Study 6638451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, methohexitone, nitrous oxide and trichloroethylene
Number of subjects: 0
Study 6638451 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no general anaesthesia
Number of subjects: 0
Study 30618285 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation (TBS) + Physical Therapy (PT)
Number of subjects: 60
Study 30618285 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) + Physical Therapy (PT)
Number of subjects: 60
Study 30618285 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT) alone
Number of subjects: 60
Study 30005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance exercise training guided by a physiotherapist twice a week and increased protein intake under the supervision of a dietitian
Number of subjects: 200
Study 30005654 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 200
Study 27502760 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual instruction (two iterations)
Number of subjects: 180
Study 27502760 — intervention group
Group type: COMPARATOR
Intervention: Combined conceptual and procedural instruction
Number of subjects: 180
Study 24158305 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient death
Number of subjects: 116
Study 24158305 — intervention group
Group type: COMPARATOR
Intervention: Simulated patient transferred to another service
Number of subjects: 116
Study 25058962 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspine rotation manipulation
Number of subjects: 134
Study 25058962 — intervention group
Group type: COMPARATOR
Intervention: Flexion manipulation
Number of subjects: 134
Study 19114175 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (Modified Vaccinia Ankara vaccine) followed by Dryvax
Number of subjects: 90
Study 19114175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist over-read of computer-generated ECG statements
Number of subjects: 90
Study 19114175 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiograms performed in subjects with abnormal ECG findings
Number of subjects: 90
Study 17686255 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metformin 1500 mg qd for 12 weeks
Number of subjects: 150
Study 17686255 — intervention group
Group type: COMPARATOR
Intervention: Glucophage (metformin, 500 mg, tid) for 12 weeks
Number of subjects: 150
Study 15086935 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 100
Study 15086935 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer Hydrochloride
Number of subjects: 100
Study 11333795 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 96
Study 11333795 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 96
Study 11333795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96
Study 11333795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 96
Study 9732190 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 104
Study 9732190 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 104